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Blood flow Restriction training After
patellar INStability (BRAINS Trial)
Benjamin D. Brightwell1 , Austin Stone1, Xiaojuan Li2, Peter Hardy1, Katherine Thompson1, Brian Noehren1† and
Cale Jacobs1*†

Abstract
Background: Patellar instability is a common and understudied condition that disproportionally affects athletes and
military personnel. The rate of post-traumatic osteoarthritis that develops following a patellar dislocation can be up
to 50% of individuals 5–15 years after injury. Conservative treatment is the standard of care for patellar instability
however, there are no evidence-informed rehabilitation guidelines in the scientific literature. The purpose of this
study is to assess the effectiveness of blood-flow restriction training (BFRT) for patellar instability. Our hypotheses
are that this strategy will improve patient-reported outcomes and accelerate restoration of symmetric strength and
knee biomechanics necessary to safely return to activity.
Methods/design: This is a parallel-group, superiority, randomized, double-blinded, placebo-controlled clinical trial
at the University of Kentucky, sports medicine clinic that aims to recruit 78 patients with acute patellar dislocations
randomly allocated into two groups: (1) sham BFRT and (2) BFRT. Both groups will receive the current standard of
care physical therapy 3 times per week for up to 9 weeks. Physical therapy sessions will consist of typical standard
of care treatment followed by BFRT or sham BFRT. Primary outcomes include the Norwich Patellar Instability Scale,
quadriceps strength, and imaging and biochemical biomarkers of cartilage degradation.
Discussion: The current standard of care for non-operative treatment of patellar instability is highly variable does
not adequately address the mechanisms necessary to restore lower extremity function and protect the long-term
health of articular cartilage following injury. This proposed novel intervention strategy uses an easily implementable
therapy to evaluate if BFRT significantly improves patient-reported outcomes, function, and joint health over the
first year of recovery.
Trial registration: Blood Flow Restriction Training, Aspiration, and Intraarticular Normal Saline (BRAINS)
NCT04554212. Registered on 18 September 2020.
Keywords: Patellar instability, Blood-flow restriction training, Rehabilitation, Randomized controlled trial

Background
Patellar dislocations are a common and understudied
condition that disproportionally affects athletes and military personnel [1]. The rate of having a patellar dislocation is greater than having an anterior cruciate ligament
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(ACL) tear in this population [1]. Regardless of intervention, 30% to 50% of those who sustain a primary dislocation experience continued pain and the sensation of
instability [2]. A significant long-term concern is the rate
of post-traumatic osteoarthritis that develops following a
patellar dislocation which can be up to 50% of individuals within 5–15 years after injury [3]. Nonoperative
treatment is currently the standard of care following
most first-time dislocations; however, 31% of patellar
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instability patients treated conservatively suffer a redislocation [4]. A single patellar dislocation increases the
lifetime risk of post-traumatic osteoarthritis (PTOA) and
recurrent dislocations markedly increase this risk [3, 5].
Therefore, there is an urgent need to minimize the incidents of recurrent patellar dislocations and PTOA sequela which safely allows an earlier return to sport or
work while also limiting long-term functional impairments and reduced quality of life.
While nonoperative treatment is most commonly
employed for patellar instability, specific evidenceinformed rehabilitation guidelines are sparse [4]. One
modality that could potentially improve treatment for
those with patellar instability is blood flow restriction
training (BFRT). BFRT involves the use of an inflatable
cuff applied to the thigh to slow arterial blood flow and
eliminate venous return as subjects exercise with a relatively low resistance. It is thought that the increased
metabolic stress and mechanical tension during BFRT
act to stimulate various metabolic pathways leading to
muscle hypertrophy [6–8]. There is evidence supporting
the premise that BFRT will result in improved quadriceps and hip strength without the need for highintensity resistance exercise [9–11]. Due to the nature of
patellar instability, patients may not tolerate highintensity quadriceps exercises early in the rehabilitation
process thus delaying the recovery of strength. BFRT
may allow them to receive the same training benefits as
if they were training under high loads. Achieving greater
muscle strength earlier after injury may result in improved lower extremity biomechanics, improved functional capacity, and an accelerated recovery.
The purpose of this double-blind randomized clinical
trial is to assess whether BFRT in addition to standard
physical therapy will improve patient-reported outcomes
and accelerate return to work or sport through the earlier restoration of symmetric strength and knee biomechanics, and reduce early cartilage degradation for those
with patellar instability.

Methods/design
Aims

The overarching rationale is that BFRT will expedite the
return to work or sports, minimize muscle impairment,
and ultimately slow cartilage degradation over the first
year following patellar dislocation. This strategy will improve patient-reported outcomes and accelerate restoration of symmetric strength and knee biomechanics
necessary to safely return to activity. We will test the following specific aims:
AIM 1: Determine if BFRT improves patient-reported
outcomes and lessens the time to return to work or
sport following patellar instability.
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Hypothesis: BFRT will result in significantly improved
responses on the patient-reported Norwich Patella Instability, visual analog scale (VAS) for Pain, Cincinnati
Occupational Rating Scale, Tegner activity scores, and
an earlier return to work and/or sport.
AIM 2: Assess whether BFRT results in more symmetric quadriceps strength and knee biomechanics following
patellar instability.
Hypothesis: BFRT will result in improved quadriceps
strength and knee biomechanics (knee moments and
excursions).
AIM 3: Compare progressive changes in cartilage degradation, muscle architecture, and inflammatory profiles
between those treated with or without BFRT over the
first 2 years.
Hypothesis: BFRT will reduce degradative changes on
Magnetic Resonance Imaging (MRI) as well as serum
and urinary biomarkers of inflammation and cartilage
degradation.
Participants

Participants will be males and females recruited from
the University of Kentucky Sports Medicine Clinic. A
sample of 78 patients with patellar instability will be recruited. Potential study participants will be identified by
members of the research team during regularly scheduled office visits with 6 physicians at the UK Orthopaedic and Sports Medicine Center. After being
identified as a potential study participant, the patient will
meet with a research assistant. Provided that the patient
meets all inclusion and exclusion criteria, a clinical research coordinator will begin the process to obtain informed consent. Before enrollment, each subject will
provide written informed consent. An American Board
of Family Medicine-certified physician with a Certificate
of Added Qualifications in Sports Medicine, aboardcertified orthopedic surgeon, or a licensed physical therapist will make the diagnosis of patellar instability utilizing the following criteria: patients’ report of at least one
episode of patellar instability within the past 3 months, a
positive patellar apprehension test during clinical examination, and no evidence on MRI or x-ray of loose body
formation or osteochondral defects, avulsion, or osteochondral defect that would require the need for surgical
intervention (Table 1).
Design

This is a parallel-group, superiority, randomized,
double-blinded, placebo-controlled clinical trial that begins in the winter of 2022 and will continue for 4 years.
This study will take place at the University of Kentucky,
and has been approved by the University of Kentucky
IRB (IRB #56541, ClinicalTrials.gov Identifier:
NCT04554212). Any changes to the protocol will be first
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Table 1 Inclusion and exclusion criteria for the BRAINS clinical
trial for patients with patellar instability
Inclusion criteria
Diagnosis of traumatic patellar dislocation (either primary or
recurrent) determined by an American Board of Family Medicinecertified physician with a Certificate of Added Qualifications in Sports
Medicine, a board-certified orthopedic surgeon, or a licensed physical
therapist utilizing clinical examination, radiographic imaging, and patients’ reports of instability
Age 14 to 40 years
Skeletally mature with closed growth plates visualized by radiograph
A score of 80 or more on the Sports Activity Scale, which corresponds
to participating in “running, twisting, turning (tennis, racquetball,
handball, ice hockey, field hockey, skiing, wrestling)” at least 1–3 times
per week
Desire to resume pre-injury activity level
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unblinded study personnel prior to the site initiation
visit. The unblinded personnel will then prepare sealed
envelopes that contain each subject’s group assignment.
All assessments and data analyses will be performed
by a separate individual to the person applying the
BFRT unit to ensure blinding. The study statistician
will generate a randomization plan using SAS or R to
assign subjects to groups. Randomization will occur
by sex and be in sets of 2 subjects to ensure adequate
distribution of all groups across the collection period.
Patients will be randomized into one of the two
following treatment groups:
1) Standard of care physical therapy + sham BFRT
2) Standard of care physical therapy + BFRT

Exclusion criteria
Concomitant osteochondral lesion requiring surgical fixation
Radiographic evidence of osteoarthritis (≥ Kellgren-Lawrence Grade 2)
Previous ipsilateral or contralateral knee surgery
Most recent instability event more than 3 months before enrollment
History of intra-articular injection into either knee within 3 months
History of any inflammatory disorder
Body mass index > 35 kg/m2
Diabetes or uncontrolled hypertension
Varicose veins or a history of personal or immediate family history
(parental or sibling) of deep vein thrombosis

reviewed by the local IRB and then communicated to
the entire study team upon approval.

Should an investigator become inadvertently unblinded, the medical officer and principal investigator
will determine the extent of the unblinding and potential
ramifications. If necessary, the investigator’s role may
need to be altered to only include tasks affiliated with
unblinded personnel. Should a patient become inadvertently unblinded, that patient’s data will continue to be
collected for safety purposes; however, the data will not
be used for the final analyses and a replacement subject
will be enrolled. Unblinding of a subject(s) group assignment will be documented and will include an explanation of why the study intervention was unblinded.
Following data lock, group assignment can be unblinded
and the unblinded information can be sent to the study
participants at the discretion of the principal
investigator.

Randomization, group allocation, and blinding

Randomization: Following informed consent and after
successfully being screened into the study based on
exam findings, subjects will be randomized to one of
two groups. The randomization schedule will be made a
predesignated unblinded study team member that will
not be involved in data collection or analysis. Using a
random number generator, allocation of to either the
BFRT or sham BFRT group will be by permutated random block size, ensuring that approximately equal numbers of subjects will be treated with drug or placebo in
the unlikely event that the study will need to be terminated prematurely. Should a subject discontinue the
study for any reason prior to the final follow-up visit,
then the collected data will be evaluated but not included in the analysis and a replacement subject will be
enrolled in the study. As such, the randomization schedule will be prepared for 100 potential participants despite having a target enrollment of 78 participants to
ensure adequate power.
Blinding: The team member that prepared the
randomization schedule will meet with the pre-specified

Interventions

All groups will receive current standard of care
physical therapy from a licensed physical therapist.
Physical therapy sessions will consist of typical
standard of care treatment followed by BFRT or
sham BFRT. The standard of care portion of the session will consist of brief subjective and objective
screening followed by a structured treatment paradigm consisting of pain modulation, neuromuscular
re-education, dynamic warm-up, range of motion
and mobility, progressive strengthening, and power
training with an emphasis on the lower extremities
and trunk musculature. The standard physical therapy portion of the treatment session will last approximately
40 min.
Interventions
for
pain
modulation, range of motion, and neuromuscular reeducation, balance, and gait training will be utilized
as needed to address individual subjects’ specific
needs at the time of screening based on the severity
of the injury and with the goal of adequately preparing them to return to their sport of choice.
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Blood flow restriction training

Two brands of blood flow restriction units will be used
(brand names not included in this text to avoid the potential for subjects to become unblinded). Subjects will
be split into groups as previously described where brand
1 will be used as sham BFRT and the intervention group
will use brand 2. All quadriceps-focused exercises will be
performed with the bands inflated. As directed by the
manufacturer’s instructions, the bands will be placed on
the proximal thigh as close to the femoroacetabular joint
as possible (Fig. 1). Limb arterial occlusion pressure will
be constantly monitored and adjusted by the unit to
maintain the desired occlusion pressure throughout the
duration of exercise. Consistent with our current trial
assessing the efficacy of BFRT for ACL reconstruction
patients (NCT03364647), participants in all groups will
perform the same exercises with an emphasis on quadriceps and hip strengthening, and for those randomized to
the active BFRT groups, each BFRT session will last approximately 20 min [12]. All subjects will attend 3 visits
per week for 8 weeks divided in to 4 phases.
The active BFRT group will have the arterial blood
flow occlusion pressure set per manufacturer instructions to achieve the desired limb occlusion pressure
(LOP), whereas the sham BFRT group will have restriction pressure set at a sub-clinical level of occlusion. Occlusion personalized tourniquet pressure (PTP) will be
reassessed each visit by rechecking the LOP. Each subject will perform a block of 4–5 quadriceps and hipfocused exercises each lasting approximately 5 min for a
total of 20 min (exercises: seated single leg press, seated
single leg knee extension, single leg forward step-ups
progressed to forward step downs when tolerated, and
resisted double leg squats). Exercise intensity will be
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adjusted between groups to accommodate the achievement of volitional fatigue and an acceptable sensation of
discomfort during exercise. Cuffs will be deflated for a
minimum of 1 min between exercises. The quadriceps
and hip strengthening exercises with the cuff donned
will be performed at the end of the rehabilitation session
with the intention of reducing the impact of fatiguing
the muscles for the standard physical therapy portion of
the treatment session.
For all subjects, rating of perceived discomfort and rating of perceived effort will be recorded from separate
11-point Likert-type scale (0 no discomfort or effort to
10 maximal discomfort or effort) for each BFRT exercise. Emphasis will be placed on distinguishing between
effort (the amount of physical energy being given to the
exercise) and discomfort (the physiological and unpleasant sensations associated with the exercise), with the
goal of maximizing effort. All exercises should be challenging and/or hard to perform; however, subjects need
to maintain proper form, as determined by the treating
physical therapist, to ensure appropriate quadriceps
engagement.
Criteria for progression of resistance or exercises include (1) no excessively aberrant movement causing pain
due to fatigue of desired muscle group(s), (2) no excessive form deviation where the desired muscle group is
no longer the primary mover completing the desired
task, (3) no concordant pain > 4/10, (4) ability to
complete delineated sets and repetitions without pausing
within a set, and (5) able to complete 2 or more repetitions than delineated during the last set of the exercise.
Criteria for clearance to return to sport include (1)
negative moving patellar apprehension test, (2) a score
of 0 indicating no effusion with the stroke test, (3) at
least 0 degrees of knee extension active range of motion
of the involved knee, (4) knee flexion active range of motion within 5 degrees of the uninvolved knee, (5) < 4/10
numeric pain rating with activity, and (6) 90% limb symmetry index as measured with isometric knee extension
peak torque and the 60-s step down test.
Treatment adherence

Fig. 1 Blood flow restriction training cuff placement. The BFRT band
is applied to the upper thigh of the subject’s leg. Pressure is
continuously regulated by the controller unit during training

Treatment adherence is the extent to which a therapist
uses interventions prescribed by a protocol. To
maximize adherence and treatment fidelity, electronic
logs of all the exercises per session will be kept on a custom Microsoft Access database. Adherence to the treatment protocol will be audited by an external physical
therapist regularly throughout the duration of the study.
We will monitor session attendance using a diary log
with participant ID numbers and session dates to track
the percentage of attendance and to account for absenteeism and reasons for missed sessions. We will make
every effort to deliver the full treatment, but we expect
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some variation in treatment delivery dose as well as
treatment drop-out. Reasons for attrition will be assessed
with an open-ended question for enrolled participants
who withdraw.
Outcome measures

Primary outcomes include the Norwich Patellar Instability Scale [13] collected at the time of enrollment, 4
weeks, 9 weeks, 6 months, and 12 months after enrollment, isometric and isokinetic quadriceps strength at 1
week, 4 weeks, 9 weeks, 6 months, and 12 months after
enrollment, MRI T1ρ and T2 relaxation times 1 week,
and 12 months enrollment, and biochemical biomarkers
which will include urinary C-terminal cross-linked telopeptide type II collagen (CTXII) and a neoepitope of
type I and type II collagen cleavage (C1,2C) at the time
of enrollment, 4 weeks, 9 weeks, 6 months, and 12
months after enrollment. Secondary outcomes include
the VAS for pain [14], Cincinnati Occupational Rating
Scale [15], Tegner Activity Scale [16], and the time to
returning to work and/or sporting activities, hip muscle
strength (hip abduction, hip external rotation), and knee
biomechanics (knee extensor moment, knee flexion excursion, knee adduction moment, knee adduction excursion) during walking, running, and anterior step-downs
1 week, 9 weeks, 6 months, and 12 months after enrollment. Data will be captured using REDCap and will be
reviewed on a quarterly basis by an unblinded member
of the study team to ensure data quality and completeness (Table 2).
Statistical methods

The primary outcome variable for Aim 1 is the Norwich
Patellar Instability Scale. Utilizing the standard deviation
of 18.6 points from our pilot results, a sample size of 34
subjects per group will be adequately powered (80%) to
detect a moderate effect size between groups difference
Table 2 Flowchart of study activities
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(13 points difference, effect size = 0.7). To protect
against up to 15% of subjects being lost to follow-up, an
additional 5 subjects will be enrolled per group (39 subjects per group; 78 total). Based on our previous pilot
work, a sample size of 34 patients per group will also be
more than 80% powered to detect group differences in
the primary outcome variables for both Aim 2 (quadriceps strength and knee biomechanics) and Aim 3 (T1ρ
relaxation time).
Since all endpoints are quantitative and longitudinal
data is collected, repeated measures analysis of covariance (ANCOVAs) will be used to assess differences in
scales across the two treatment groups (BFRT vs. sham
BFRT). The repeated measures ANCOVAs will adjust
for demographic covariates (e.g., age, sex, and race) as
well as look for differences across any other potential
confounders (such as first-time vs. repeated instability
events). Assumptions such as normality and constant
variance will be assessed, and remedial measures will be
employed as needed. In addition, interaction effects and/
or variable transformations will be explored appropriately. In the case that endpoints are related, multivariate
analysis of covariance (MANCOVAs) may be used to
consider those that naturally group themselves.
All analyses will be performed with a significance level
of 0.05, and appropriate multiple comparisons adjustments will be performed as needed. Categorical variables
will be described with counts and percentages and analyzed using appropriate statistical methods, such as hypothesis tests or logistic regression models.
For both primary and secondary analyses, in the case
of participants that violate group allocation or do not attend a minimum of 80% of the prescribed physical therapy sessions, we will perform intention-to-treat and per
protocol analyses. We will not employ imputation
methods in the case of missing data. No interim or other
subgroup analyses will be performed.
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Participant information will be combined with information from other people taking part in the
study. When we write about the study to share it
with other researchers, we will write about the combined information we have gathered. Participants will
not be personally identified in these written materials. We may publish the results of this study; however, we will keep participant names and other
identifying information private. The study information collected from participation in the study may be
entered into a secure computer system. The study
physician is committed to maintaining the privacy of
every study participant and any personal information
submitted and follows the principles of the Health
Insurance Portability and Accountability Act (HIPA
A) of 1996. All data are stored at a secure site behind a firewall, which monitors and protects against
unauthorized access. Participant charts and any other
items containing confidential items will be stored in
a safe place overnight and not left on the desk.
Charts will not be left in an area where others might
have access to them. Participants should know, however, that there are some circumstances in which we
may have to show their information to other people.
For example, the law may require us to show their
information to a court or to tell authorities if they
report information about a child being abused or if
they pose a danger to themselves or someone else.
Officials of the University of Kentucky, the Department of Defense, members of an independent Data
Safety Monitor Board, the Center for Clinical and
Translational Science, and Bluegrass Research Consultants may look at or copy pertinent portions of
records that identify participants. Participants withdraw from the study or are withdrawn; data collected to that point will be kept.
Monitoring

We will utilize the standing independent Data Safety
Monitoring Board (DSMB) as chartered by the Center
for Clinical and Translational Science (CCTS). The
DSMB will meet three times per year or as needed and
will review participant recruitment, AE’s, side effects, laboratory results, dropouts, protocol violations, and inclusion/exclusion criteria. More frequent meetings will take
place if side effects or other problems are prevalent.
Should an adverse or serious adverse event occur, the research participant will be followed by physicians, registered nurses, and other research staff members for the
duration of the participant’s hospitalization. Routine care
will be provided by hospital staff. Emergency medical
equipment, medications, and supplies will be at the physician’s disposal should the participants have an acute
untoward reaction.
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Discussion
Currently, scientific evidence regarding the medical
management and treatment of patellar instability is
sparse. As such, the standard of care for non-operative
treatment is highly variable does not adequately address
the mechanisms necessary to restore lower extremity
function and protect the long-term health of articular
cartilage and surrounding musculature following injury.
A significant need remains to identify novel therapies
that successfully restore function and preserve joint integrity. The goal of this trial is to evaluate if augmenting
standard physical therapy with BFRT significantly improves patient-reported outcomes, function, and joint
health over the first 2 years of recovery.
Blood-flow restriction training is a promising modality
for patients who suffer from patellar instability. We have
previously shown that these individuals have clinically
important impairments in quadriceps and hip strength
as well as altered knee biomechanics compared to
healthy volunteers [17]. Increased quadriceps strength
has been shown to be protective against patellofemoral
cartilage loss as well as improved pain and function [18].
Hip weakness and increased knee abduction angles may
place the patient at greater risk for repeated lateral patellar dislocation or subluxation and increase the compressive and shear forces born by the articular cartilage [18,
19]. BFRT allows the subject to exercise with light resistance to derive similar training benefits seen with higherintensity resistance exercises (Fig. 1) [6–10, 20–23]. Potentially, with BFRT the negative morphological adaptations of hip and thigh musculature that result in
abnormal lower extremity biomechanics can be addressed, while compressive and shear forces born by the
patellofemoral articular cartilage are minimized thereby
promoting recovery [11, 19].
We seek to address the shortcomings of the current
treatment strategies by specifically addressing progressive cartilage degradation, muscle weakness, and functional impairment for those with patellar instability.
Current physical therapy protocols do not adequately restore quadriceps or hip muscle strength resulting in altered knee biomechanics. The combination of a proinflammatory intra-articular environment and persistent
biomechanical deficits undoubtedly contribute to the
high rate of PTOA for those with patellar instability. By
potentially addressing both biologic and biomechanical
mechanisms of PTOA, the proposed interventions may
alter the progression of PTOA in this high-risk patient
population. The long-term impact of this study is that
the progression of PTOA may be delayed or potentially
even avoided. These results may then impact the treatment paradigms for other acute conditions such as anterior cruciate ligament injuries, shoulder dislocation,
and/or ankle sprains.
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Trial status
This is protocol version 2.0 (December 15, 2021). Patient
recruitment will begin in January 2022 with recruitment
ending December 2023.
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metalloproteinase-3; VAS: Visual analog scale; MRI: Magnetic resonance
imaging; LOP: Limb occlusion pressure; PTP: Personalized tourniquet
pressure; ANCOVAs: Analysis of covariance; MANCOVAs: Multivariate analysis
of covariance
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Biological specimens
Laboratory analyses of biologic samples outcomes: Data sheets will record
descriptive information on the biopsy when collected (number of tubes,
etc.). Samples will be labeled according to the visit the study participant
attended. The sample tubes will be labeled with the participant’s study ID
number first. For example, when collecting data subject 05 on visit 2, the
images will be labeled as PI05_V2 followed by the type of fluid. For biologic
samples, similar identifiers will be used with _urine or _serum used to
identify the type of fluid (example: PI05_V2_urine).
Blood samples: Standard venipuncture will be used to collect 10 mL blood
samples at each of the five study visits. The PI and research coordinator have
both completed the UK Phlebotomy Class and completed the “Phlebotomy
Clinical Training and Competency Validation” form to allow drawing blood
samples from study subjects. In addition, the 4 other research coordinators
in the Department of Orthopaedic Surgery and Sports Medicine have also
been trained and certified in phlebotomy. While not key personnel in the
current study, they will be added to the study personnel list to act as backups should both the study coordinator and PI not be available to perform
the study blood draws.
Urine samples: Similarly, urine samples will be collected at all 5 study visits.
The Functional Orthopedics Assessment Laboratory (FOAL) is located within
the clinical space at the UK Orthopaedic and Sports Medicine Center. There
is a dedicated, lockable restroom located next door to the FOAL which
allows participants a private area to provide a urine sample, and the sample
can then be discreetly transferred from the restroom to the FOAL.
Sample processing: Blood and urine samples will be collected at all study
time points. Serum and urine samples will be initially processed in the FOAL.
Blood and urine samples will be spun in a refrigerated centrifuge at 3500
RPM for 10 min. Serum and urine will then be aliquoted into separate prelabeled cryovials. Samples will be initially stored on site at − 80 °C in a
freezer, and subsequently transferred from the clinical facility to the University of Kentucky Orthopaedic Biomarker Repository for analysis (UK’s Charles
T. Wethington Building, Room 443) on a monthly basis.
With the participant’s approval and as approved by local Institutional Review
Boards (IRBs), de-identified biological samples will be stored at the UK Orthopedic Biomarker Repository. These samples could be used to research the
causes of osteoarthritis after meniscus injury, its complications, and other
conditions for which individuals with meniscus injuries are at increased risk,
and to improve treatment. The UK Orthopedic Biomarker Repository (CTW
443) will also be provided with a code-link that will allow linking the biological specimens with the phenotypic data from each participant, maintaining the blinding of the identity of the participant.
During the conduct of the study, an individual participant can choose to
withdraw consent to have biological specimens stored for future research.
However, withdrawal of consent with regard to bio-sample storage may not
be possible after the study is completed.
When the study is completed, access to de-identified study data and/or samples will be available from the principal investigator on reasonable request.
At the conclusion of the study, biologic samples will be analyzed in the UK
Biomarker Analysis Laboratory.
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